Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse ...

In this manuscript, Yao et al. present solid evidence to show that MnMYL3 may serve as a receptor for NNV via macropinocytosis. This manuscript is valuable for understanding the molecular mechanisms ...

Tevogen Bio’s platform shows potential, but financial challenges persist. Read why TVGN stock remains a "Hold" due to funding ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

Stimulus selectivity was lowest in the AON (mean=4.1±1.5 SD) and gradually increased from aPCx (3.0±1.0) to LEC (2.3±0.7), CA1 (2.4±0.8), and SUB (2.3±0.8 ... geranyl acetate, salicylaldehyde, ...

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a ...

Diabetes researchers and bioinformaticians from the Icahn School of Medicine at Mount Sinai have developed a new ...